# BioVie Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/BioVie Inc). ## Overview BioVie Inc. is a clinical-stage biopharmaceutical company focused on developing drug candidates for neurological and neurodegenerative disorders as well as advanced liver disease. Its pipeline centers on bezisterim (NE3107), an orally administered small molecule being studied for inflammatory and insulin-resistance pathways implicated in Alzheimer’s disease, Parkinson’s disease, and Long COVID, and BIV201, a continuous-infusion terlipressin program for liver disease. The company does not currently generate revenue and remains dependent on clinical progress and external financing to fund development. BioVie is a very small organization with a lean internal team and heavy reliance on outside scientific, clinical, and regulatory partners. ## Products & services • Bezisterim (NE3107) for neurodegenerative disorders • BIV201 continuous-infusion terlipressin for advanced liver disease • Clinical development of drug candidates • Regulatory and commercialization planning for future approvals - **Neurology / neurodegenerative pipeline** (55%) — Development of bezisterim for Alzheimer’s disease, Parkinson’s disease, and related inflammatory neurodegenerative indications. - **Hepatology / liver disease pipeline** (45%) — Development of BIV201, a continuous-infusion terlipressin program aimed at advanced liver disease. - Bezisterim (NE3107) for neurodegenerative disorders - BIV201 continuous-infusion terlipressin for advanced liver disease - Clinical development of drug candidates - Regulatory and commercialization planning for future approvals ## Customers BioVie does not sell commercial products today; its direct counterparties are clinical trial participants, investigators, contract research organizations, laboratories, and other development vendors that enable its programs. If approved, its future customers would likely include physicians, hospitals, and specialty treatment centers prescribing therapies for Alzheimer’s disease, Parkinson’s disease, Long COVID-related inflammation, and advanced liver disease. The company’s end-market is therefore the healthcare system rather than a traditional recurring customer base, with demand driven by unmet medical need and regulatory approval. In the near term, the company’s economic survival depends more on capital providers than on product buyers because it has no revenue and no commercial launch yet. - **Clinical development partners** (primary) — CROs, trial sites, principal investigators, and labs that execute studies and support regulatory submissions. - **Future healthcare prescribers** (secondary) — Physicians and specialty clinics that could prescribe bezisterim or BIV201 if approved. - **Patients with neurodegenerative disease** (secondary) — Patients with Alzheimer’s disease, Parkinson’s disease, or Long COVID-related inflammatory conditions who represent the eventual treatment population. - **Patients with advanced liver disease** (secondary) — Patients who may benefit from BIV201 in advanced liver disease settings if development succeeds. - **Financing counterparties** (primary) — Equity investors and other capital providers that fund operations before any product revenue exists. - Clinical trial sites and investigators running studies for bezisterim and BIV201 - CROs and laboratories providing outsourced development services - Potential future prescribers such as neurologists and hepatology specialists - Hospitals and treatment centers that would use approved therapies - Capital markets investors funding development before commercialization ## Geography BioVie is headquartered in the United States and its disclosed commercial and scientific focus is primarily U.S.-based. The company also references competition and scientific activity in Europe and elsewhere, indicating that its therapeutic targets are global in scope even though development is still early. Because it has no revenue and no commercial manufacturing footprint disclosed, geography currently matters more for where trials, regulatory interactions, and future market opportunities may occur than for sales concentration. The company’s exposure is therefore tied to U.S. FDA approval pathways and the ability to access international clinical and capital markets as programs advance. - Headquartered in the United States - Clinical and regulatory focus is centered on U.S. FDA pathways - Competitive set includes biopharma firms in the United States and Europe - No commercial revenue geography disclosed because the company has no revenue - Future market opportunity could extend beyond the U.S. if products are approved ## Strategy BioVie’s strategy is to advance a small number of high-conviction clinical assets rather than build a broad commercial portfolio. The company is prioritizing development of bezisterim and BIV201 through clinical trials, regulatory work, and intellectual property protection in order to create approvable product candidates. Because it has no revenue, capital formation is a core strategic activity and the company explicitly expects to fund operations through equity sales, loans, or strategic transactions. The business model therefore depends on converting clinical data into regulatory value while preserving enough liquidity to continue development. - **Advance clinical trials for bezisterim and BIV201** (short-term) — Clinical data is the main value-creation engine for a company with no revenue and no approved products. - **Secure additional financing** (short-term) — The company has substantial operating cash burn and explicitly states that continued operations depend on external capital. - **Strengthen intellectual property and regulatory positioning** (medium-term) — Patent protection and FDA approval are essential to create defensible commercial value from the pipeline. - Advance bezisterim through clinical development for neurodegenerative disease - Progress BIV201 as a liver disease program with retained development and marketing rights - Protect intellectual property through patents, trade secrets, and exclusivity - Use external financing and strategic transactions to fund operations - Rely on outsourced clinical and regulatory execution to keep the organization lean ## Risks BioVie faces the classic risks of a clinical-stage biotech company: failure in clinical development, regulatory setbacks, and dependence on third parties to run trials. The company explicitly states that it relies on CROs, clinical sites, investigators, laboratories, manufacturers, and suppliers, so execution risk is partly outside management’s control and can delay or derail approval. It also has no revenue and has disclosed substantial doubt about its ability to continue as a going concern, making financing risk a central business risk rather than a secondary concern. More broadly, the company competes against larger biopharmaceutical firms with greater capital, broader IP portfolios, and more resources to sustain long development cycles and patent disputes. - **Clinical development failure** [critical] — The company’s value depends on proving safety and efficacy in trials for bezisterim and BIV201. - **Dependence on third-party trial execution** [high] — CROs, sites, investigators, and labs control key parts of the development process and can miss deadlines or fail compliance requirements. - **Going-concern / financing risk** [critical] — The company has no revenue and states that future operations depend on additional financing. - **Competition from larger biopharma firms** [high] — Competitors have greater resources, broader IP portfolios, and more ability to fund long development timelines. - **Intellectual property uncertainty** [medium] — Patent applications may not issue or be enforceable, reducing protection for future products. - Clinical trial failure or delays could prevent approval of bezisterim or BIV201 - Dependence on CROs and other third parties creates execution and compliance risk - No revenue and ongoing losses create going-concern and financing risk - Competition from larger biopharma companies can outspend and outlast the company - Patent and IP challenges could weaken exclusivity and future pricing power - Regulatory uncertainty can delay commercialization or impose post-approval restrictions ## Accounting BioVie’s accounting is dominated by development-stage judgments rather than revenue recognition, since the company has not generated revenue and does not expect revenue in the foreseeable future. Research and development expense is a key estimate area because it includes clinical trial costs, consultants, supplies, and accrued external research obligations that can fluctuate materially as studies progress. The company also reports derivative liabilities and related fair value changes, which can create non-cash volatility in other income and expense and make period-to-period comparisons difficult. Stock-based compensation is another important item because the company uses equity awards to conserve cash, and grant-date valuation assumptions affect reported operating loss. Liquidity disclosures and going-concern assessments are especially important because the financial statements depend heavily on management’s assumptions about future financing and operating runway. - **Research and development accruals** — Affects operating loss and quarterly comparability - **Derivative liabilities at fair value** — Creates earnings volatility - **Stock-based compensation** — Raises reported operating expenses - **Going-concern and liquidity disclosures** — Frames solvency and financing risk - No revenue recognition currently, so the income statement is driven by operating expenses and financing items - Clinical trial and consulting accruals affect research and development expense timing - Derivative liability fair value changes can create non-cash volatility in other income/expense - Stock-based compensation affects reported losses and reflects cash-conservation strategy - Going-concern assessment depends on management’s financing assumptions and cash runway - Grant program accounting may affect how certain awards or support are recognized --- *Last updated: 2026-09-24T11:09:27.991076+00:00*